Recent 8-K filings for SGP

• May 14, 2026, 4:15 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction

  Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.

• March 26, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  SpyGlass Pharma reports FY2025 net loss $39.9M; positive Phase 1/2 data and $172.5M IPO

  Net loss of $12.6M in Q4 2025 ($5.72/sh) and $39.9M for FY2025 ($17.98/sh).

• March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops

  97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.

• February 13, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02

  SpyGlass Pharma discloses FY2025 performance cash bonuses for named executive officers

  Compensation Committee approved FY2025 bonuses on Feb 12, 2026.

• February 9, 2026, 6:59 PM ET other material materiality 0.90 positive item 5.02item 5.03item 7.01item 9.01 ◈ Governance Changes ×2

  SpyGlass Pharma closes IPO, raises $172.5M at $16.00/share

  Closed IPO of 10,781,250 shares (incl. full exercise of underwriters' option for 1.4M additional shares) at $16.00/share.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

3 positive 0 negative 2 neutral

source · SGP on sec.gov